A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers

European Journal of Contraception and Reproductive Health Care

Volumn 5, Issue 4, 2000, Pages 256-264

  Blode, H ^a   Wuttke, W ^b   Loock, W ^c   Roll G ^d   Heithecker, R ^c  

^a Research Pharmacokinetics   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c Global Clinical Development   (Germany)

^d Clinical Operations Biostatistics II   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRACEPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; ESTRADIOL BLOOD LEVEL; FEMALE; HORMONAL CONTRACEPTION; HORMONE PROTEIN COMPLEX; HUMAN; ORAL CONTRACEPTION; PRIORITY JOURNAL;

EID: 0034473223     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/13625180008500407     Document Type: Article

References (17)

1. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: Effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women
2. The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and anti-androgenic potential
3. Dihydrospirorenone (ZK30595): A novel synthetic progestagen - Characterization of binding to different receptor proteins
4. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism
5. Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity
6. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel
7. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone
8. Radioimmunological analysis of ethinylestradiol in human serum
9. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy
10. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: Serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum
11. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: Serum protein binding of levonorgestrel and influence on free and total testosterone levels in the serum
12. Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin
13. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles
14. Pharmaco-kinetics of levonorgestrel and ethinylestradiol in 9 women who received a low dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation
15. Pharmaco-kinetics and serum protein binding of 3-ketodesogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive
16. Pharmaco-kinetics and protein binding of gestodene under treatment with a low-dose combination oral contraceptive for three months
17. A single-dose and 3-month clinical pharmacokinetic study with a new combination oral contraceptive